Session 2: New Drug Update - Part I: Including New Indications and Dosage Forms |
||||||
|
||||||
C. Wayne Weart,Pharm.D., FASHP,FAPhA, BCPS Dr. Weart is on the speakers bureau for Novartis, in the area of hypertension and Pfizer in the areas of cardiovascular disease and pain. He is a consultant for Merck in the area of outcomes research. |
At the conclusion of this presentation, the participant should be able to:
Objectives:
|
|||||







